Abstract
Abstract Heart valve tissue engineering and regeneration represents a novel, and viable alternative treatment modality for valvular heart disease. Tissue-engineered pulmonary valves (TEPV) have been constructed from autologous cells
Highlights
Valvular heart disease is a significant cause of morbidity and mortality; annually, there are over 100, 000 valve replacements in the US [1]
Heart valve tissue engineering has captured the popular imagination of investigators and patients alike
While the discussion here is focused on the pulmonary valve (PV), bone marrow mesenchymal stem cells (BM-Mesenchymal stem cells (MSCs)) can certainly be used for tissue engineering of the other three heart valves with equal success
Summary
Valvular heart disease is a significant cause of morbidity and mortality; annually, there are over 100, 000 valve replacements in the US [1]. While the discussion here is focused on the PV, bone marrow mesenchymal stem cells (BM-MSCs) can certainly be used for tissue engineering of the other three heart valves with equal success. Data shown in (Figure 1) demonstrates the ability of BM-MSCs to form mesodermal tissue— mesenchymal, cartilaginous, ECM components, SM and nonsmooth muscle which makes them a viable cell source for heart valve engineering.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
